Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 5/20 | 0.51 |
| ▸ | SGK1 | O00141 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601528 | 0.85 | ALK (0.60) | ALKSGK1CYP2C19NMT1 | |
| SCHEMBL1599780 | 0.79 | ALK (0.52) | ALKSGK1CYP2C19 | |
| SCHEMBL12707559 | 0.78 | ALK (0.67) | ALKSGK1MET | |
| SCHEMBL19908204 | 0.76 | ALK (0.58) | ALKMET | |
| SCHEMBL19908175 | 0.75 | ALK (0.60) | ALKMET | |
| SCHEMBL1601187 | 0.74 | ALK (0.58) | ALKSGK1MET | |
| SCHEMBL3603995 | 0.72 | ALK (0.60) | ALKMET | |
| SCHEMBL1601069 | 0.71 | ALK (0.67) | ALKMET | |
| SCHEMBL1602401 | 0.71 | ALK (0.47) | ALK | |
| SCHEMBL1601322 | 0.70 | ALK (0.81) | ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7919502-B2 | Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | ALK, MET, RET | ALK 1/4885SGK1 1253/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.